HIV-1 viral load blips are of limited clinical significance

The Journal of Antimicrobial Chemotherapy
Patricia K LeeRichard E Nettles

Abstract

Many patients on highly active antiretroviral therapy (HAART) who achieve undetectable HIV-1 RNA levels experience transient episodes of detectable viraemia or blips, suggesting there is incomplete suppression of viral replication. This raises concern that drug resistance mutations could develop and cause eventual treatment failure. However, data from recent studies indicate that most blips are actually random biological and statistical variations around a mean viral load below detectable levels (<50 copies/mL) or due to false elevations of viral load from laboratory processing artefacts. Blips are not typically associated with the development of resistance mutations and most importantly are not associated with virological or clinical failure of previously adequate HAART.

References

Jul 13, 2001·JAMA : the Journal of the American Medical Association·D V HavlirJ K Wong
Sep 28, 2002·AIDS·Gilbert GreubUNKNOWN Frankfurt HIV Clinic Cohort and the Swiss HIV Cohort Study
Feb 17, 2005·JAMA : the Journal of the American Medical Association·Richard E NettlesRobert F Siliciano
Nov 4, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Valentina StosorRobert L Murphy

❮ Previous
Next ❯

Citations

Sep 23, 2008·Transactions of the Royal Society of Tropical Medicine and Hygiene·F MaldonadoR Zachariah
Dec 27, 2008·Transactions of the Royal Society of Tropical Medicine and Hygiene·David WilsonNattayapa Taochalee
Jul 5, 2011·Nature Reviews. Gastroenterology & Hepatology·Fabien Zoulim
Dec 5, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alexandra CalmyWilliam Rodriguez
Jan 15, 2010·The Journal of Antimicrobial Chemotherapy·Jose M Gatell
Jan 28, 2012·American Journal of Respiratory and Critical Care Medicine·Thomas J ScribaHassan Mahomed
Jun 20, 2014·Journal of the International AIDS Society·Bruno HoenUNKNOWN 2013 French HIV expert group
Jun 24, 2014·Enfermedades infecciosas y microbiología clínica·UNKNOWN Panel de expertos de GeSIDA, UNKNOWN Plan Nacional sobre el Sida
Oct 29, 2013·Enfermedades infecciosas y microbiología clínica·UNKNOWN Panel de expertos de GeSIDA y Plan Nacional sobre el Sida
Nov 26, 2011·Journal of Pain and Symptom Management·Jessica S MerlinIan Frank
Jun 18, 2010·Enfermedades infecciosas y microbiología clínica·UNKNOWN Panel de Expertos de Gesida, UNKNOWN Plan Nacional sobre el Sida
Jun 23, 2009·Journal of Theoretical Biology·Libin Rong, Alan S Perelson
May 12, 2015·Enfermedades infecciosas y microbiología clínica·UNKNOWN Panel de expertos de GeSIDA y Plan Nacional sobre el Sida
Feb 15, 2015·Journal of Theoretical Biology·Daniel Sánchez-Taltavull, Tomás Alarcón
Jul 31, 2013·Current Opinion in Virology·Christian Selinger, Michael G Katze
Oct 31, 2012·Journal of Theoretical Biology·Denis Fils Nkoa OnanaDjomangan Adama Ouattara
Sep 12, 2013·PloS One·Ninon TaylorHannes Oberkofler
Oct 30, 2016·The Journal of Infectious Diseases·Brandon M ImpVictor G Valcour
Jan 24, 2014·International Journal of STD & AIDS·Jill BlumenthalSheldon Morris
Sep 20, 2015·Journal of the International Association of Providers of AIDS Care·Dharmalingam ThirunavukarasuThirunavukarasu Umaarasu
Jun 23, 2009·International Journal of STD & AIDS·S M CasserlyM Macdougall
Dec 20, 2017·Journal of Neurovirology·Benjamin B GelmanDennis Kolson
Jul 18, 2014·Journal of Clinical Microbiology·Allyson V RitchieHelen H Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.